- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer
This study is testing a new combination of drugs, ociperlimab and tislelizumab, against a standard treatment, pembrolizumab, for a serious type of lung cancer. The aim is to see if the new combination can help people live longer and improve their quality of life.
For: Locally advanced · unresectable · or metastatic non small cell lung cancerPoland · France · Spain - Active not recruitingPHASE3
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
This study looks at a new drug, zanidatamab, combined with chemotherapy, and sometimes another drug called tislelizumab. It aims to see if this treatment works better and is safer than standard chemotherapy for advanced stomach and gullet cancers that have HER2.
For: Gastric Neoplasms · Gastroesophageal Adenocarcinoma · Esophageal AdenocarcinomaArgentina · Australia · Belgium - Active not recruitingPHASE2
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
This study is looking at a new treatment called tislelizumab, sometimes combined with other medicines, for head and neck cancer that has come back or spread. The aim is to see if it can shrink tumours and if it's safe for patients.
For: Head and Neck Squamous Cell Carcinoma · Head and Neck CancerUnited States · Australia · Canada - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 with Tislelizumab in Patients with Advanced Solid Tumors
This study looks at new drug combinations (BGB-A425, LBL-007, and Tislelizumab) for advanced head and neck, kidney, and lung cancers. It aims to find safe doses and see if they shrink tumours. It's an early-stage study.
For: Head and Neck Squamous Cell Cancer · Renal Cell Carcinoma · Non-Small Cell Lung CancerFrance · Spain · Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)
This study is testing new combinations of medicines for advanced stomach or gastroesophageal junction cancer. It's looking at how safe they are and how well they help control the cancer, especially in people with a specific marker called DKK1-high.
For: Gastric cancer · Gastric Adenocarcinoma · GastroEsophageal CancerGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This study is testing new combinations of medicines to treat a type of head and neck cancer that has come back or spread. Doctors are looking at how well these new treatments shrink the cancer and if they are safe.
For: Head and Neck Squamous Cell CarcinomaFrance · Italy · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase II, Open-Label Study of preliminary efficacy of Sitravatinib in Combination with Tislelizumab in Patients with Metastatic Uveal Melanoma with liver metastases.
This study is looking at a new combination of medicines, Sitravatinib and Tislelizumab, for people with a type of eye cancer called uveal melanoma that has spread to the liver. We want to see how well this combination shrinks the cancer.
For: Uveal melanomaSpain - Active not recruitingPHASE3
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
This study looks at the long-term safety of a drug called zanubrutinib for people with certain blood cancers (B-cell malignancies). It's for those who have already taken zanubrutinib in a previous study.
For: B-cell MalignanciesUnited States · Australia · China - AuthorisedTherapeutic confirmatory (Phase III)
Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
This study looks at new treatments for advanced lung cancer that has become resistant to previous immune-boosting therapies. It compares a combination of N-803, tislelizumab, and docetaxel against docetaxel alone, aiming to see if the combination helps people live longer.
For: Advanced or Metastatic Non-Small Cell Lung CancerGermany · Hungary · Spain - AuthorisedTherapeutic exploratory (Phase II)
A Phase II, Open-Label, Single-Arm, Multicentre Study of Carboplatin, Paclitaxel, and Tislelizumab in Biomarker-Selected Patients with Resectable Locally Advanced Oral Cavity Squamous Cell Carcinoma - PERSEPHONE Trial
This study looks at a new combination of medicines (chemotherapy with a drug called tislelizumab) for people with a certain type of mouth cancer that can be removed with surgery. We want to see how well this combination shrinks the tumour before surgery.
For: Resectable Locally Advanced Oral Cavity Squamous Cell CarcinomaItaly